title: Antidepressant medication use and breast cancer risk.
abstract: OBJECTIVE
  Most epidemiologic studies have detected no association between prior use of antidepressant medications and breast cancer risk. Despite the uniform conclusion, there is a continuous rise in the proportion of women using antidepressants, lending support to further monitoring of disease effects.
  
  
  METHODS
  We conducted a population-based case-control study among 2908 incident breast cancer cases diagnosed from 2003 to 2006, and 2927 control women from Wisconsin. Associations between antidepressant use and breast cancer risk were evaluated using multivariable logistic regression.
  
  
  RESULTS
  The association between use of antidepressant medications and breast cancer risk was null (OR = 0.89, 95%CI 0.78-1.01). When stratified by type of antidepressant, use of selective-serotonin reuptake inhibitors (SSRIs) resulted in a similar risk overall (OR = 0.85, 95%CI 0.72-1.00) and among former and currents users. There were no associations between other types of antidepressant classes and breast cancer risk. In assessing risks among the five most commonly used antidepressants, we detected no association with fluoxetine, sertraline, venlafaxine, or buproprion hydrochloride. There was a reduction in breast cancer risk of 36% (OR = 0.64, 95%CI 0.45-0.92) among users of paroxetine hydrochloride. When stratified by body mass index, there was a reduction in risk associated with antidepressant users who were not overweight (OR = 0.73, 95% CI 0.60-0.90), but this association was null in overweight women (p-interaction = 0.04).
  
  
  CONCLUSIONS
  Surveillance of health risks associated with antidepressant medications continues to be of public health importance, though these medications are not likely to be associated with breast cancer risk.
authors.affiliation: Program in Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. kwernli@fhcrc.org
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Wernli
authors.forename: John M
authors.initials: JM
authors.lastname: Hampton
authors.forename: Amy
authors.initials: A
authors.lastname: Trentham-Dietz
authors.forename: Polly A
authors.initials: PA
authors.lastname: Newcomb
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D016017:Odds Ratio; D011159:Population Surveillance; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014922:Wisconsin / Q000453:epidemiology
chemical_list: D000928:Antidepressive Agents